Stocktoria
Korro Bio, Inc. KRRO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-10-03
Korro Bio, Inc. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 | FY2023 | FY2022 | FY2022 | FY2022 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0 | — | — | — | $0 | — | — | — |
| R&D expense | $65.6M | $63.6M | $57.2M | — | — | — | $42.2M | — | — | — |
| Operating income | -$121.9M | -$91.9M | -$84.5M | — | — | — | -$59.0M | — | — | — |
| Interest expense | — | — | — | — | — | — | $961,000 | — | — | — |
| Income tax | $637,000 | $141,000 | $27,000 | $0 | $0 | $0 | $10,000 | $0 | $0 | $0 |
| Net income | -$117.3M | -$83.6M | -$81.2M | — | — | — | -$58.0M | — | — | — |
| EPS (diluted) | $-12.48 | $-9.37 | $-53.08 | — | — | — | $-227.42 | — | — | — |
| Operating cash flow | -$78.6M | -$60.1M | -$67.3M | — | — | — | -$53.6M | — | — | — |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M | — | — | — | -$58.8M | — | — | — |
| Cash & equivalents | $21.8M | $55.6M | $166.2M | $41.7M | $39.7M | $40.9M | $36.3M | $43.8M | $42.4M | $49.8M |
| Total assets | $113.5M | $226.2M | $221.7M | $46.3M | $79.4M | $101.5M | $73.7M | $136.0M | $149.7M | $164.9M |
| Total liabilities | $62.1M | $65.8M | $51.8M | $9.6M | $34.0M | $48.3M | $8.9M | $54.0M | $53.8M | $52.3M |
| Shareholders' equity | $51.4M | $160.4M | $169.9M | -$153.3M | -$135.4M | -$118.2M | -$99.0M | $82.0M | $95.9M | $112.7M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 | FY2023 | FY2022 | FY2022 | FY2022 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +181.5% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.